Stay updated on Cabozantinib for Adrenocortical Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Cabozantinib for Adrenocortical Carcinoma Clinical Trial page.

Latest updates to the Cabozantinib for Adrenocortical Carcinoma Clinical Trial page
- Check6 days agoNo Change Detected
- Check14 days agoNo Change Detected
- Check21 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check35 days agoNo Change Detected
- Check42 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1%
- Check49 days agoChange DetectedThe website has been updated from version v2.14.1 to v2.14.2.SummaryDifference0.1%
- Check63 days agoChange DetectedThe website has been updated from version v2.14.0 to v2.14.1.SummaryDifference0.1%
- Check71 days agoChange DetectedThe type of intervention has been updated from version v2.13.3 to v2.14.0.SummaryDifference0.2%
- Check100 days agoChange DetectedNew results for Progression-free Survival (PFS) based on RECIST 1.1 criteria were posted on December 10, 2024, along with updated study documents from M.D. Anderson Cancer Center, while previous results and detailed secondary outcome measures from April 2024 were removed.SummaryDifference8%
Stay in the know with updates to Cabozantinib for Adrenocortical Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cabozantinib for Adrenocortical Carcinoma Clinical Trial page.